Try our Advanced Search for more refined results
Life Sciences - April, 2018
300 articles
- Insurers Seek To Nix Antitrust Suit Over Allergy Testing
- Berkeley Defends Bid To Overrule PTAB In CRISPR Row
- Vaccine Co. Pulls Suit Over Clinical Trial Into Fed. Court
- Jury Convicts Mass. Doc Of Giving Patient Info To Drug Co.
- Pfizer, Insurer Duel Over Venue For $30M Coverage Fight
- Hidden Expert-Pay Ruling Won't Improve J&J Odds At Retrial
- Migraine Patent Case Doomed By 10-Year Delay, Judge Rules
- Lawyer's Loose Lips Get Zimmer New Trial On $9M Damages
- Cooley Reps SteadyMed In $216M Sale To United Therapeutic
- Fed. Circ. Says Bid To Revisit VA Contract Ruling Too Late
- 3 Fla. Bellwether Cases Settled In Abilify MDL
- Don't Sleep On The Dormant Commerce Clause
- The Fastest Federal Civil Court For A Decade
- Ex-NECC Employees Don't Want Jury To Hear Of Drug Harms
- J&J Urges Court To Toss $117M Verdicts In NJ Talc Case
- Biogen Must Face FCA Suit Minus 17 State-Level Claims
- FTC Says Impax Must Sell 10 Generics After Amneal Deal
- Justices Seem Wary Of Strict Int'l Deference Standard
- 6 Firms Will Steer IPOs Totaling About $693M To Start May
- SEC Can Monitor Mass. Medical Co. Amid Fraud Charges
- DePuy Wins Infringement Damages Cap For Missing IP Marks
- A More Mobility-Friendly Approach To Noncompetes In Ill.?
- Bayer, J&J Beat Claims In Latest Philly Xarelto Trial
- Intuitive Says Doc's Deal Undercuts $2M Robot Fraud Claim
- Divided 7th Circ. Revives Atty's Age Discrimination Suit
- Merck Hit With Antitrust Suit Over Vaccine Bundle Discounts
- Serono Fights Biogen's Retrial Bid Over Nixed MS Drug Patent
- Atty Cites 1st Circ. In Seeking Contempt In Biolitec IP Case
- Attys Want $1.2M Fees From Forest Labs Gender Bias Deal
- Teva Settles Case Over Alleged Info Sharing With Rival CEO
- Israeli Med Device Developer Closes $70M Series C Round
- Ranbaxy Takes Patent Arbitration Fight To Texas Justices
- Pleading A Personal Jurisdiction Defense Late In The Game
- Hidden Expert Pay Gets J&J New Trial After $502M Verdict
- Transfer Of Lipozene Class Action Stands, 9th Circ. Says
- Texas Lab Wants Judge To Rethink $30.6M FCA Judgment
- Deals Rumor Mill: Eli Lilly, TransUnion, Quality Care
- Pfizer Slams Out-Of-State Claims Over Robitussin Label
- Fed. Circ. Says Merck Atty's Lies Doomed $200M Patent Win
- GSK, Zofran Users Bicker Over Scope Of Patient Discovery
- Dems Concerned House Opioid Bills Too Rushed
- Counterfeit Cosmetics: Fake Beauty, Real Danger
- Bristol-Myers Squibb: A Dangerous Sword
- Illumina DNA Patent Previously Found Valid, PTAB Says
- FDA Warning Wire: Spring Storm Over Youth E-Cig Sales
- Genentech Asks Fed. Circ. To Affirm Nix Of Inducement Claims
- Hong Kong OKs Listing Reforms To Allow Dual-Class Stock
- LabCorp Hit With Antitrust Suit Over Del. Medicaid Services
- Justices Ask What Deference US Courts Owe Foreign Gov'ts
- Deals Rumor Mill: Takeda, HNA Group, Didi
- Eyedrops Ruling Invites 'Abusive' Suits, High Court Hears
- Valeant Can Add NY Investor Fraud Suit To 27 Others In NJ
- Biotech Co. Execs Charged In $12.7M Painkiller Fraud
- Takeda Inches Closer To Shire Buy With £46B Offer
- Bard Seeks New Trial Over Vein Filters After $3.6M Verdict
- Antitrust Damages Analysis Can Respect International Comity
- Aspire Universal Unveils $300M Precision Medicine Fund
- Ballard Can't Arbitrate IP Malpractice Suit, Judge Told
- AbbVie Disputes $3M AndroGel Verdict In MDL Bellwether
- Arthrex Denied 2nd Shot At Estoppel Challenge By Fed. Circ.
- Akorn Sues Fresenius Over Nixed $4.3B Merger
- EU, Mexico Agree To Broader Trade Deal Nixing Tariffs
- Construction Firm Leads 4 IPO Launches Totaling $468M
- 3 Sentenced In $16.6M Fraudulent Medical Device Scheme
- Docufilm Maker Denied Access To Theranos Depo Videos
- Accutane Testimony Wasn't Reliable, NJ Justices Told
- Genetics Co. Hid Cancer Test Overbilling, Investor Says
- Allergan To Pay $500K To End Calif. Faulty Lap-Band Claims
- How States, Federal Agencies Are Challenging Drug Prices
- Medical Device Cybersecurity: Preparing For The Worst
- Investors, Pernix Set $75M Stalking Horse Bid For Orexigen
- FDA's Essure Order Affirms Role Of Learned Intermediary
- Cephalon's $125M Antitrust Deal Is Valid, Atty Power Unknown
- Alnylam, Dicerna Settle Trade Secrets Case Ahead Of Trial
- Vitamin C Importers Urge Less Int'l Deference At High Court
- Janssen Escapes Whistleblower Suit Over Off-Label Opioids
- 6 Firms To Guide Tech-Heavy IPO Lineup Set To Exceed $1.3B
- Shire Weighing Revised £44B Buyout Offer From Takeda
- Disney Workers Urge 9th Circ. To Revive Valeant ERISA Suit
- Oregon Tribe Sues Pharma Cos. Over Opioid Epidemic
- Bayer, J&J Can't Nix Xarelto Case Midtrial, Patient Says
- Experts Look To Congress To Stem Patent-Eligibility 'Chaos'
- MiraLAX Generics Get FDA Reprieve Despite Bayer Objections
- Health Hires: Goodwin, Shook Hardy, Michael Best, Orrick
- Ex-Aveo CFO Denied Quick Win In SEC's Cancer Drug Suit
- Taxation With Representation: Freshfields, Thompson, Davis
- Fed. Circ. Revives Medinol Patent Suit Killed By Laches
- Tax Critic Laments Federal Code's Effect On Marijuana Market
- Will High Court Ever End Circuit Split Over FCA Pleading?
- Biogen Pays Pharma Co. Ionis $1B To Extend Partnership
- FDA Offers Guidance On Making Opioid Addiction Treatments
- Pa. Court Won't Derail State's Medical Marijuana Program
- Rule 23 Changes: Avoid Delays In Class Settlement Approval
- CytRx, Class Dispute $685K Pump & Dump Deal Fee Award
- Judge Unseals $2 Million Fee Request In Adderall Patent Suit
- Bio-Pharm Must Face Generic-Drug Supply Contract Suit
- 3 IPOs Tap Markets For $841M With Mixed Results
- Amneal Says Fed. Circ. Redo In Drug Patent Row Unnecessary
- Allergan, Tribe Fight PTAB's Immunity Denial At Fed. Circ.
- 5 Takeaways As DEA Mulls Slashing Opioid Output
- Bayer, J&J Urge Judge To Ax Philly Xarelto Case Midtrial
- Abbott Must Give Docs To Alere Investors In Stock-Drop Suit
- Pfizer Gets Final Nod On $94M Celebrex Antitrust Settlement
- Boehringer Ducks TCPA Suit Over Faxed Seminar Invites
- Jones Day Guides P&G's €3.4B Buy Of Merck Health Brands
- The Flawed European Remedy To Bayer-Monsanto Deal
- Shire Spurns £44B Takeover Offer From Takeda
- Hundreds Seek To Centralize NJ Taxotere Hair Loss Suits
- Fed. Circ. Affirms PTAB Ax Of Cialis, Adcirca Patents
- Ex-Pharma Staffing Exec Gets Noncompete Suit Tossed
- Deals Rumor Mill: Altice, Carl Icahn, Grail
- Pharmacy, PE Fund Owner Want Tricare FCA Suit Trashed
- Best Practices For Building A Better Meeting
- Momenta, Sandoz Ask To Appeal Antitrust Claims Mid-Suit
- Eye Drop Suit Must Stay Tossed, Pharma Cos. Tell 1st Circ.
- UK Patent Ruling Sharpens Contrast With US Practice
- Missouri Talc Decision Could Signal Mass Tort Sea Change
- DEA Proposes Capping Opioid Quotas
- W.Va. Reaches $550K Settlement With Shuttered Pill Mill
- Pfizer, Ranbaxy Look To Dump State Claims In Lipitor MDL
- Calif. Court Revives Avandia Injury Claims Against GSK
- FDA Warning Wire: Mosquitoes, Gnats And Fungus, Oh My
- 5 Ways Law Firms Are Becoming More Like Hotels
- Allergan To Pay $3.5M To Resolve Lap-Band FCA Allegations
- Advent In Talks To Buy Sanofi Euro Generics Arm For $2.3B
- Fed. Circ.'s Latest Guidance On Method-Of-Treatment Claims
- Dropping Ranks: Lathrop's Rough Patch
- Dropping Ranks: Andrews Kurth's Pre-Merger Dip
- Why BigLaw's Partnerships Are Shrinking
- Dropping Ranks: Stroock's 'Shrink To Grow' Strategy
- Miami Launches Suit Against Drug Cos. Over Opioid Abuse
- NJ High Court Urged To Consolidate J&J Hernia Mesh Suits
- Confidentially Marketed Public Offerings Carve Bigger Niche
- Highlights Of ABA Antitrust Spring Meeting: Part 1
- Fed. Circ. Affirms IP Win For Sunovion On Generic Latuda
- Jones Day Grabs Ex-Freshfields Litigator, Arbitration Pro
- PTAB Denies 2 More Challenges To Maquet Blood Pump IP
- Gorsuch's 1st Year Shows He Is A Conservative Activist
- J&J Won't Get High Court Look At FCA 'Particularity' Rule
- OvaScience Board Ducks Shareholders' IVF Treatment Suit
- Cooper-Vemedia Pays Sanofi $195M For 12 Pharma Brands
- Shire Inks $2.4B Sale Of Cancer Biz As Takeda Eyes Takeover
- Supreme Court Seeks Gov't View Of Gilead FCA Case
- Megafirms Find New Heights In Grounded Market
- How 5 Firms Grew Without Merging
- The Law360 400
- Law360 Reveals 400 Largest US Firms
- Vanda Schizophrenia Drug Patentable, Fed. Circ. Says
- Ex-Katten Atty Pushes To Deep-Six Fraud Verdict
- Canadian Drug Cos. To Pay $34M For Selling Phony Products
- SEC Charges Supplement Co. CEO With Penny Stock Fraud
- Big Dental Distributors Can't Brush Off Antitrust Suit
- 8 Firms To Steer IPOs Exceeding $2.6B As April Heats Up
- Chinese Gov't To Argue Before High Court In Vitamin C Case
- Aggrenox End-Payors Want $18M Atty Fees In $54M Deal
- 4th Circ. Finds Md. Drug Pricing Law Unconstitutional
- Pfizer Can't Shake Suit Over Deceptive Robitussin Labels
- Funds Fight Bids To Toss $80B Valeant Price-Gouging Suit
- A Chat With Baker Botts CMO Gillian Ward
- Deals Rumor Mill: PAG Asia, Mylan, SpaceX
- Bard Hit With $35M Punitive Damages In NJ Mesh Case
- Celgene Sues To Block Dr. Reddy's Revlimid Generic
- Sanofi's FCA Suit Docs Not All Privileged, Ex-Worker Says
- FDA Bans Bulk Sale Of Concentrated Caffeine Supplements
- Preempting Preemption: Device Cases After Shuker — Part 2
- NuVasive Urges 9th Circ. To Toss $27M Poaching Verdict
- Full Fed. Circ. Won't Take On Ariosa Re-Exam Challenge
- Sorin Denies Family's Claim It Hid Heart Valve Info From FDA
- Avee Objects To Abbott Dismissal Move In $36M Escrow Suit
- Fed. Circ. OKs PTAB's Trim Of Luitpold Iron Patents
- States Expanding Efforts To Tackle Prescription Drug Prices
- FDA Unveils Guidance On DNA Testing Technology
- Task Force Makes 11 Drug-Related Arrests On Tribal Lands
- J&J Unit Wants Whistleblower Docs In Hip Implant FCA Suit
- Unraveling FDA's Recent Flurry Of Tobacco Activity
- Texas Doctor Charged With Trading Xanax For Favors
- Drugmakers Duped Medicaid Rebate Regulators, 3rd Circ. Told
- FDA Proposes New Way To Approve Updated Medical Devices
- Fenwick To Move NYC Office To Tech Hub Flatiron District
- Bard Hit With $33M Pelvic Mesh Verdict In NJ
- What Cos. Need To Know About China's New Market Regulator
- Fed. Circ. Case May Change Biosimilar IPR Strategy
- Preempting Preemption: Device Cases After Shuker — Part 1
- Finance-Savvy Millennials Are Shifting Business Of Law
- Orexigen Reaches Deal With Creditors On $70M DIP Loan
- Opioid MDL Judge Sets Litigation Plan, Bashes DEA
- Bard Hustled Defective Meshes To Market, Jury Told In Closing
- FTC Appeals Big Loss To A Shire Unit In Sham Petition Case
- Ropes & Gray Advises Alexion's $855M Swedish Drug Co. Buy
- Navajo Nation Is Latest To Sue Pharma Cos. Over Opioids
- PTAB Rightfully Rejected Merck Patent App, Fed. Circ. Says
- USPTO Head Calls For New Path To Restore Patent Stability
- Lewis Brisbois Nabs Product Liability Atty For Philly Office
- Farmers Win OK Of $1.5B Syngenta GMO Corn Settlement
- Theranos, Walgreens Dodge Some Claims In Blood Test Row
- Teva Investor Suit Over $40.5B Merger Sent To Conn.
- EU OKs Bayer's Divestiture To BASF In $62B Monsanto Deal
- J&J Hit With $80M Punitive Damages Verdict In NJ Talc Case
- Attorney-Client Privilege Is Alive And Well
- Dissolving Practice
- J&J Fights Bid For Punitive Damages In Asbestos Talc Case
- Shkreli Must Repay Investor $388K Over Property Deal Woes
- Orexigen Noteholders Say $70M DIP Loan Strips Value
- Device Cos., Hospital Sue 18 Cos. Over Anti-Aging Microneedles
- Deals Rumor Mill: Sprint, L'Oreal, Sinochem
- Drugmakers Assail FDA For Nixing Generic Laxative Approval
- Par Pharma Blasts $102M Bond Ask In Trade Secrets Suit
- FDA Warning Wire: Dead Raccoon, Too-Strong Cough Syrup
- Littler Brings 2 Former Shareholders Back To Chicago
- PTAB To Review Hair Loss Treatment Patent After Rehearing
- Dissolving Practice: How To Fix A Dysfunctional Law Firm
- 5 Attys Tapped For Pharmacy Negotiating Team In Opioid MDL
- Pro Tennis Orgs Hit With Player's $10M Blood Draw Injury Suit
- Ballard Spahr Wants IP Rental Malpractice Claims Arbitrated
- Deals Rumor Mill: Bayer, Viacom, Haidilao
- Illumina Urges Court To Uphold Jury Verdict Against Ariosa
- FDA Slaps 'Unique' Limit On Bayer's Essure Sales
- White House Asked To Produce Info On Opioid Crisis Work
- Cancer-Focused Biopharma Co. Snags $100M From Investors
- Dissolving Practice: Partner Agreement Clauses That Can Help
- Amgen's Patent Not Used In Neulasta Biosimilar, Mylan Says
- Novartis Buys Gene Therapy Co. Avexis In $8.7B Deal
- The Time Is Right For New Jersey To Adopt Daubert
- Medical Device Cos. Deny FCA Suit's Excess Blood-Test Claim
- Mylan Can Sell Generic Of Shire's Lialda, Fed. Circ. Confirms
- Cogentix Hit With Stockholder Class Challenge To $239M Sale
- 2 Firms To Guide IPOs Totaling $170M Led By Tech Startup
- 9th Circ. Reinvigorates Sex Aid Supplement Suit
- Bayer, J&J Botched Xarelto Bleeding Warning, Pa. Jury Told
- Calif. County Can't Escape Hemp Seizure Suit, Court Told
- Health Hires: Dentons, Greenberg Traurig, Morgan Lewis
- Ariad Investors' Attys Seek 30% Of $3.5M Class Settlement
- Dissolving Practice: The Unfinished Business Doctrine
- Drug Cos., Pharmacies Want Pause In Cherokee Opioid Suit
- Congress' Fix To Tribal Sovereign Immunity Misses The Point
- China Not Backing Down After Latest US Tariff Threat
- Trans-Pacific Partnership Lost Important IP Provisions
- What To Do After A Product Recall
- Maine Lab Will Arbitrate Mice Row With University
- Hong Kong Aims To Grab Bigger Share Of Global Listings
- Bard Meshes Didn't Harm Woman, Harvard Doctor Tells Jury
- Otsuka, Bristol Seek Quick Win On Abilify Fail-To-Warn Claims
- Impax's $20M Settlement In Pay-For-Delay Suit Clears Hurdle
- Trump Floats New Tariffs As US-China IP Scrap Intensifies
- Aussie DNA Test Co. Keeps Win In Patent Row With Texas Dr.
- China Tells Justices It Faced Hostility In Vitamin C Case
- Ill. Pharmacist Gets 4 Years For $2.4M Insurance Fraud
- Nonprofits Urge HHS To Take Over Sarepta's Exondys Patents
- Ex-NHL Owner Conned Investors Out Of $14M, SEC Says
- AbbVie Inks Humira IP Licensing Deal With Samsung Bioepis
- Sandoz Rehashed Arguments In Rituxan IP Challenge: PTAB
- Aetna HIV Privacy Suit Goes Back To Calif. State Court
- 1st Circ. Upholds Sarepta Win In Drug Trial Investor Suit
- CardioNet's Heart Monitor Patents Get Trimmed Under Alice
- MusclePharm Sues Liberty Again Over SEC Case Costs
- 3rd Circ. Affirms Merck Win In Shingles Vaccine Case
- PetIQ's Deal To Buy Veterinary Clinic Chain Faces Challenge
- J&J Hit With $37M Asbestos Talc Verdict In NJ
- J&J Case Raises Estoppel Issue For Successful IPR Litigants
- Applying The Business Judgment Rule To Director Pay Claims
- What To Do During A Product Recall
- J&J Loses Mistrial Bid Over Claims At Asbestos Talc Trial
- McKesson Hit With FCA Suit Alleging Misbranded Drugs
- Chinese Scientist Gets 10 Years For Plot To Steal GMO Seeds
- Judge Tosses Teva Investors' Price-Fixing Suit From Bench
- Supplement Co. Manager Cops To Selling Illegal Stimulants
- FDA Head Puts Spotlight On Internet's Role In Opioid Crisis
- Okla. Tribe Says Drug Cos. Played Major Role In Opioid Abuse
- Fla. Medical Pot Provider Challenges Dispensary Limits
- Brookfield-Backed GrafTech Launches $850M IPO
- Prescribing Doc's Testimony Key In 2nd Philly Xarelto Trial
- 3 New Settlements Highlight DOJ Scrutiny Of Device Makers
- Tribe Says Cannabis Co.'s $10M Suit Based On Void Contract
- 'Malpractice' By A Computerized Decision-Support Tool?
- Bard Can't Get Surgery Kit Patent Suit Out Of Illinois
- From Rocket Launchers To Soybeans: US, China At The Brink
- VC Firm Sofinnova Raises €275M For Life Science Investments
- What To Do Before A Product Recall
- Lawmaker, IP Orgs Contest On-Sale Bar Ruling At High Court
- Deals Rumor Mill: CBS, Pfizer, Mediaset
- J&J Tests Weren't Meant To Find Asbestos In Talc, Jury Told
- Vitamin Shoppe Answer Claims It Pumped Up Powder Benefits
- AbbVie Says Suit Over Nixed $54B Shire Merger Should End
- USTR Targeting Chinese Goods In Clash Over IP Rules
- Texas Lab Must Pay $30.6M For Inflated Mileage Charges
- Another Cops To Bribery Over NJ Medical Device Contract
- Fed. Circ. Clears PTAB's Trim Of EMED Needle Shield Patent
- Latham Adds Wilson Sonsini Corporate Partner In Calif.
- King & Spalding Nabs Cooley IP Trial Partner
- Rival Hits MiMedx With $6.8M Breach, Trade Secrets Suit
- DOJ Looks To Help Resolve Opioid MDL As Friend Of Court
- Innovator Liability Is The Least Scary Thing About Rafferty
- NN Scoops Up PE-Backed Medical Device Co. In $375M Deal
- J&J Says At Trial's Close Its Talc Tested Free Of Asbestos
- Merck Says Holding Co. Must Arbitrate Pay-For-Delay Claims
- No Fees For Roche Or Nova After Failed IP, Breach Row
- Kimberly-Clark, Halyard Get $450M Punitives Slashed
- Global Health Care Compliance: Spotlight On Korea
- Biotech Startup Seres Beats Suit Over Stock Drop
- Innovator Liability: A Pandora's Box For Pharma Cos.?